Top Markets
#1 Pleasing Gold Pleasing Gold +1,501.98%
#2 Ontology Gas Ontology Gas +151.18%
#3 PulseChain PulseChain +57.64%
#4 ConstitutionDAO ConstitutionDAO +37.37%
#5 Osmosis Osmosis +32.13%
#6 BOOK OF MEME BOOK OF MEME +31.44%
#7 Ontology Ontology +29.58%
#8 Neiro Neiro +29.12%
#9 Collect on Fanable Collect on Fanable +28.84%
#10 Unit Pump Unit Pump +27.30%
Coin of the day
Pleasing Gold Pleasing Gold
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Mendus AB (publ) Mendus AB (publ)

Mendus AB (publ)

IMMU
Rangering i aksjer #25836
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Aksjekurs
$0.74834668
Markedsverdi
$45.86M
Endring (1 dag)
-0.15%
Endring (1 år)
-6.28%
Land
SE
Handel Mendus AB (publ) (IMMU)

Kategori

Healthcare
Inntekter for Mendus AB (publ) (IMMU)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Mendus AB (publ) er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Mendus AB (publ) fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US